 Tejas Patil
Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 39 | 2026 | 1188 | 6.520 |
Why?
| | Lung Neoplasms | 44 | 2026 | 2662 | 4.970 |
Why?
| | Protein Kinase Inhibitors | 16 | 2026 | 979 | 1.820 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2026 | 1958 | 1.810 |
Why?
| | Acrylamides | 7 | 2025 | 74 | 1.720 |
Why?
| | Aniline Compounds | 7 | 2025 | 120 | 1.670 |
Why?
| | Mutation | 19 | 2026 | 4071 | 1.600 |
Why?
| | ErbB Receptors | 15 | 2025 | 635 | 1.300 |
Why?
| | Antibodies, Monoclonal | 3 | 2025 | 1505 | 1.210 |
Why?
| | B7-H1 Antigen | 3 | 2026 | 243 | 1.110 |
Why?
| | Protein-Tyrosine Kinases | 7 | 2023 | 431 | 0.930 |
Why?
| | Receptor, ErbB-3 | 1 | 2025 | 48 | 0.920 |
Why?
| | Proto-Oncogene Proteins | 7 | 2023 | 623 | 0.910 |
Why?
| | Pleural Neoplasms | 3 | 2026 | 30 | 0.910 |
Why?
| | Neuregulin-1 | 1 | 2025 | 49 | 0.900 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2026 | 881 | 0.880 |
Why?
| | Pemetrexed | 1 | 2024 | 40 | 0.860 |
Why?
| | Pyrimidines | 11 | 2026 | 530 | 0.840 |
Why?
| | Immunoconjugates | 1 | 2025 | 138 | 0.790 |
Why?
| | Brain Neoplasms | 6 | 2024 | 1328 | 0.730 |
Why?
| | Proto-Oncogene Proteins c-ret | 4 | 2026 | 41 | 0.670 |
Why?
| | Mesothelioma | 3 | 2026 | 51 | 0.620 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2025 | 992 | 0.620 |
Why?
| | Gene Rearrangement | 6 | 2026 | 155 | 0.600 |
Why?
| | Medical Oncology | 4 | 2026 | 338 | 0.580 |
Why?
| | Aged, 80 and over | 12 | 2026 | 8318 | 0.580 |
Why?
| | Adenocarcinoma | 3 | 2026 | 920 | 0.560 |
Why?
| | Neoplasms | 4 | 2026 | 2900 | 0.530 |
Why?
| | Aged | 24 | 2026 | 26096 | 0.520 |
Why?
| | Middle Aged | 29 | 2026 | 36126 | 0.510 |
Why?
| | Indoles | 7 | 2025 | 507 | 0.490 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 12 | 0.480 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 104 | 0.440 |
Why?
| | Biomarkers, Tumor | 6 | 2026 | 1320 | 0.430 |
Why?
| | Pyrazoles | 6 | 2026 | 517 | 0.410 |
Why?
| | Humans | 54 | 2026 | 145140 | 0.400 |
Why?
| | Survival Rate | 7 | 2026 | 2087 | 0.400 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2026 | 640 | 0.400 |
Why?
| | Retrospective Studies | 21 | 2026 | 17247 | 0.390 |
Why?
| | Adult | 18 | 2026 | 40665 | 0.370 |
Why?
| | Neoplasm Staging | 7 | 2026 | 1467 | 0.360 |
Why?
| | Disease Progression | 4 | 2025 | 2857 | 0.350 |
Why?
| | Female | 31 | 2026 | 78636 | 0.350 |
Why?
| | Male | 28 | 2026 | 72664 | 0.330 |
Why?
| | Antineoplastic Agents | 5 | 2024 | 2207 | 0.300 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2023 | 254 | 0.300 |
Why?
| | Prognosis | 5 | 2026 | 4310 | 0.280 |
Why?
| | Lung | 2 | 2018 | 4101 | 0.280 |
Why?
| | Proto-Oncogene Proteins c-met | 3 | 2026 | 76 | 0.270 |
Why?
| | Molecular Targeted Therapy | 4 | 2026 | 438 | 0.260 |
Why?
| | Pyridines | 4 | 2026 | 608 | 0.240 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2026 | 9 | 0.240 |
Why?
| | Neoplasm Metastasis | 3 | 2024 | 688 | 0.230 |
Why?
| | Genomics | 3 | 2026 | 819 | 0.230 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2025 | 264 | 0.220 |
Why?
| | Thymoma | 1 | 2025 | 37 | 0.220 |
Why?
| | Thymus Neoplasms | 1 | 2025 | 30 | 0.220 |
Why?
| | Central Nervous System | 3 | 2023 | 281 | 0.220 |
Why?
| | Thoracic Neoplasms | 1 | 2025 | 39 | 0.220 |
Why?
| | Lactams | 2 | 2025 | 28 | 0.210 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2026 | 121 | 0.210 |
Why?
| | Neoadjuvant Therapy | 2 | 2024 | 465 | 0.200 |
Why?
| | Oncogenes | 3 | 2022 | 118 | 0.200 |
Why?
| | Aminopyridines | 2 | 2025 | 129 | 0.200 |
Why?
| | Oncogene Addiction | 1 | 2023 | 6 | 0.190 |
Why?
| | Research Personnel | 1 | 2025 | 184 | 0.190 |
Why?
| | Radiosurgery | 2 | 2024 | 399 | 0.180 |
Why?
| | Chemoradiotherapy | 1 | 2024 | 239 | 0.180 |
Why?
| | Soft Tissue Neoplasms | 1 | 2023 | 128 | 0.180 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 1058 | 0.180 |
Why?
| | Acetonitriles | 1 | 2021 | 12 | 0.170 |
Why?
| | Bone Neoplasms | 1 | 2023 | 255 | 0.170 |
Why?
| | Sarcoma | 1 | 2023 | 204 | 0.160 |
Why?
| | Circulating Tumor DNA | 1 | 2020 | 46 | 0.150 |
Why?
| | Gene Amplification | 1 | 2019 | 118 | 0.150 |
Why?
| | Lactams, Macrocyclic | 1 | 2019 | 51 | 0.150 |
Why?
| | Tracheal Neoplasms | 1 | 2019 | 12 | 0.150 |
Why?
| | Genes, erbB-1 | 1 | 2018 | 21 | 0.140 |
Why?
| | Piperazines | 1 | 2021 | 375 | 0.140 |
Why?
| | Oncogene Proteins | 1 | 2018 | 61 | 0.140 |
Why?
| | Transcriptome | 1 | 2024 | 1029 | 0.130 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 117 | 0.130 |
Why?
| | Thromboembolism | 1 | 2018 | 129 | 0.130 |
Why?
| | Disease-Free Survival | 2 | 2017 | 766 | 0.130 |
Why?
| | Computed Tomography Angiography | 1 | 2018 | 146 | 0.130 |
Why?
| | Biomarkers, Pharmacological | 1 | 2017 | 26 | 0.130 |
Why?
| | Smad4 Protein | 1 | 2017 | 34 | 0.130 |
Why?
| | Gene Deletion | 1 | 2018 | 391 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 279 | 0.130 |
Why?
| | Erlotinib Hydrochloride | 1 | 2017 | 72 | 0.120 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 198 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2020 | 5411 | 0.110 |
Why?
| | Carbazoles | 2 | 2026 | 53 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 1146 | 0.110 |
Why?
| | Piperidines | 2 | 2026 | 220 | 0.100 |
Why?
| | Prospective Studies | 1 | 2025 | 8035 | 0.100 |
Why?
| | Treatment Outcome | 5 | 2026 | 11741 | 0.100 |
Why?
| | Colorectal Neoplasms | 1 | 2021 | 864 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 2 | 2022 | 2767 | 0.090 |
Why?
| | Liver Neoplasms | 1 | 2018 | 775 | 0.090 |
Why?
| | Mice | 2 | 2026 | 18303 | 0.090 |
Why?
| | Smoking | 1 | 2018 | 1470 | 0.090 |
Why?
| | Gene Fusion | 2 | 2023 | 30 | 0.090 |
Why?
| | Incidence | 1 | 2018 | 2915 | 0.080 |
Why?
| | Quality of Life | 1 | 2022 | 3194 | 0.080 |
Why?
| | Survival Analysis | 2 | 2025 | 1371 | 0.070 |
Why?
| | Animals | 2 | 2026 | 37952 | 0.060 |
Why?
| | Biomarkers | 1 | 2017 | 4282 | 0.060 |
Why?
| | Myasthenia Gravis | 1 | 2025 | 24 | 0.060 |
Why?
| | Pleura | 1 | 2024 | 28 | 0.050 |
Why?
| | Consolidation Chemotherapy | 1 | 2024 | 11 | 0.050 |
Why?
| | Tropomyosin | 1 | 2023 | 10 | 0.050 |
Why?
| | Receptor, trkA | 1 | 2023 | 18 | 0.050 |
Why?
| | Canada | 1 | 2025 | 429 | 0.050 |
Why?
| | Peritoneum | 1 | 2023 | 43 | 0.050 |
Why?
| | Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 18 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2023 | 190 | 0.050 |
Why?
| | Platinum | 1 | 2023 | 48 | 0.050 |
Why?
| | Taxoids | 1 | 2023 | 114 | 0.050 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2022 | 21 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2026 | 530 | 0.050 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2023 | 101 | 0.040 |
Why?
| | Exons | 1 | 2023 | 363 | 0.040 |
Why?
| | Thyroid Neoplasms | 1 | 2026 | 350 | 0.040 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2023 | 212 | 0.040 |
Why?
| | Young Adult | 1 | 2018 | 14176 | 0.040 |
Why?
| | Appendiceal Neoplasms | 1 | 2021 | 28 | 0.040 |
Why?
| | Meningeal Neoplasms | 1 | 2021 | 95 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 231 | 0.040 |
Why?
| | Precision Medicine | 1 | 2024 | 459 | 0.040 |
Why?
| | Signal Transduction | 2 | 2026 | 5208 | 0.030 |
Why?
| | Protein Conformation | 1 | 2021 | 936 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2026 | 3539 | 0.030 |
Why?
| | Algorithms | 1 | 2025 | 1845 | 0.030 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2017 | 19 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1763 | 0.030 |
Why?
| | Etoposide | 1 | 2017 | 167 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 223 | 0.030 |
Why?
| | Cranial Irradiation | 1 | 2017 | 85 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2024 | 1188 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 968 | 0.030 |
Why?
| | Deoxycytidine | 1 | 2017 | 220 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2017 | 165 | 0.030 |
Why?
| | Immunotherapy | 1 | 2020 | 665 | 0.030 |
Why?
| | Registries | 1 | 2024 | 2401 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1546 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 618 | 0.030 |
Why?
| | DNA Repair | 1 | 2017 | 254 | 0.030 |
Why?
| | United States | 2 | 2025 | 16065 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 474 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5988 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1264 | 0.030 |
Why?
| | Databases, Factual | 1 | 2019 | 1488 | 0.020 |
Why?
| | Mass Screening | 1 | 2020 | 1354 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1442 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3410 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3892 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2351 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7182 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 7107 | 0.020 |
Why?
| | Adolescent | 1 | 2023 | 22479 | 0.010 |
Why?
| | Child | 1 | 2023 | 22670 | 0.010 |
Why?
|
|
Patil's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|